Recent updates of therapeutic strategy of esophagogastric junction adenocarcinoma
作者机构：Department of Gastroenterological SurgeryCancer Institute Hospital of Japanese Foundation of Cancer ResearchTokyo 135-8550Japan.
出 版 物：《Journal of Cancer Metastasis and Treatment》 (癌症转移与治疗（英文版）)
年 卷 期：2021年第7卷第1期
页 面：727-736页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金： (20K09046)
主 题：Esophagogastric junction adenocarcinoma Barrett’s esophagus microsatellite instability molecular subtype
摘 要：The incidence of esophagogastric junction(EGJ)adenocarcinoma has been increasing in Asian *** the recent advances in multidisciplinary treatments,EGJ adenocarcinoma remains aggressive with unfavorable *** surgical strategy,EGJ adenocarcinoma arises between the esophagus and the stomach,and thus tumor cells spread through the lymphatic system both upward to the mediastinum and downward to the ***,an optimal extent of lymphadenectomy remains *** drug therapy,the latest topic in gastric and EGJ adenocarcinoma is trastuzumab deruxtecan,which is an antibody-drug conjugate consisting of an anti-HER2 *** addition,many clinical trials have recently demonstrated the efficacy of immune checkpoint ***,recent advances in sequencing technology have revealed that gastroesophageal adenocarcinoma could be categorized into four molecular subtypes:epstein-Barr virus-associated,high-level microsatellite instability,genomically stable,and chromosomal instability ***,these subtypes show distinct clinical phenotypes and molecular *** review the current surgical strategy and drug treatment such as molecular-targeted agents,immune checkpoint inhibitors,and molecular-subtype-based therapeutic strategies in EGJ *** and molecular characteristics and response to immune checkpoint inhibitors differ among molecular *** strategies based on molecular subtypes may be clinically beneficial for patients with EGJ adenocarcinoma.
维普期刊数据库